{"id":"NCT03812510","sponsor":"Aclaris Therapeutics, Inc.","briefTitle":"Safety Study of A-101 Topical Solution for the Treatment of Common Warts","officialTitle":"A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-07","primaryCompletion":"2019-11-27","completion":"2019-12-20","firstPosted":"2019-01-23","resultsPosted":"2020-11-23","lastUpdate":"2020-11-23"},"enrollment":426,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Common Wart"],"interventions":[{"type":"DRUG","name":"A-101","otherNames":["hydrogen peroxide 45%"]}],"arms":[{"label":"A-101","type":"EXPERIMENTAL"}],"summary":"A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts","primaryOutcome":{"measure":"Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts","timeFrame":"Baseline to a maximum of 341 days","effectByArm":[{"arm":"A-101 45% (Active)","deltaMin":70,"sd":null},{"arm":"Isopropyl Alcohol and Water (Vehicle)","deltaMin":116,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":46,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":376},"commonTop":["Application site pain","Application site pruritus","Application site infection","Application site pallor","Application site scab"]}}